BioPharmSignal logoBioPharmSignal

Biotech News

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange

Enlivex Therapeutics (ENLV)Enlivex TherapeuticsCommercial

Listing expected to expand market access and secondary liquidity for Enlivex's primary digital treasury asset

Nes-Ziona, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, "Enlivex" or "the Company") today reported that its primary treasury asset, the RAIN token, has been listed on...

Related news

ENLVEnlivex Therapeutics2026-06-24 13:00 EST

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume

ENLVEnlivex Therapeutics2026-07-30 13:00 EST

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

REPLReplimune Group2026-08-19 20:01 EST

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CADLCandel Therapeutics2026-06-25 12:05 EST

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

IBRXImmunityBio2026-08-10 13:00 EST

ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

BCTXBriaCell2026-07-07 11:30 EST

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

PHARPharming Group2026-08-13 05:00 EST

Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older

CUECue Biopharma Inc2026-06-02 20:05 EST

Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution

IBRXImmunityBio2026-06-01 17:51 EST

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

BCTXBriaCell2026-06-25 11:30 EST

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

View all latest news

Enlivex Therapeutics

Enlivex Therapeutics is an immunotherapy company focused on macrophage reprogramming and inflammation-related disease. Its story is centered on harnessing innate immunity to address hard-to-treat conditions.

Recent company news

ENLVEnlivex Therapeutics2026-07-30 13:00 EST

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

Stock data

Close
1.47 USD
Market cap
204.87M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States